Heidelberg Pharma GmbH is a pharmaceutical company with a dual business model: (A) Providing preclinical drug development services in general with a special focus on the development of ADCs. Heidelberg Pharma has ample experience in providing antibody-drug conjugate related services to its clients. (B) Development of novel therapeutics in oncology based on its own proprietary 2nd generation ADC technology based on a novel toxin.
Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena’s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals. Abzena works with most of the top 20 biopharmaceutical companies and academic groups all over the world and is focused on enabling the development of better treatments for patients. Abzena’s technologies have enabled many of its customers to progress products through to clinical development. Abzena was created through the incorporation of Antitope, PacificGMP, PolyTherics and The Chemistry Research Solution (TCRS); all of whom now trade as Abzena.
Avipep Therapeutics is a pre-clinical stage biotech company that develops next-generation ADCs based upon the company's proprietary Avibody™ platform.
Avibodies™ are small, stable, high avidity antibody-derivatives that have superior biodistribution and tumor penetration compared with traditional intact IgGs. Clinical trial results in cancer patients have shown that Avibodies can rapidly and efficiently penetrate tumors. They durably persist within the tumor for weeks while clearing from the systemic circulation within hours.
Avibodies can deliver highly potent payloads with far less toxicity and can be reformatted from existing intact antibodies. Please contact us to discuss collaboration or license.
BioPharma Translationsinstitut Dessau
BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. BSP Pharmaceuticals is focused on innovative therapies such as Proteosome Inhibitors, Antibody Drug Conjugates (ADCs) , Liposomal formulations, handling the major platforms of ADC compounds currently in clinical and commercial phase.
Cerbios has the experience and capabilities to move your ADC project forward. We support you from early stage bioconjugation POC studies up to cGMP manufacturing for both cytotoxic and non-cytotoxic ADCs. Furthermore we provide you with development and manufacturing services for highly potent cytotoxic payloads.
Full life cycle services (including experienced consultancy, full CMC support, registration/validation material and commercial production) are granted for each project.
Heraeus, the precious metals and technology group headquartered in Hanau, Germany, is a global, private company with 160 years of tradition. Our fields of competence include precious metals, materials, and technologies, sensors, biomaterials, and medical products, as well as dental products, quartz glass, and specialty light sources. With product revenues of €4.1 billion and precious metal trading revenues of €17.9 billion, as well as more than 12,900 employees in over 120 subsidiaries worldwide, Heraeus holds a leading position in its global markets.
Iksuda Therapeutics (formally Glythera) is a pre-clinical stage company developing ADCs for difficult to treat solid tumours. Our ADCs are centered around our proprietary PermaLInk® conjugation platform which provides conjugation stability by design.
Through PermaLink, we aim to develop more effective ADCs by leveraging the broad tumour activity associated with ultra-potent DNA damaging payloads, combined with clinically relevant targets.
Through our collaborations and partnerships, we are building a pipeline of superior ADCs with the goal of improving the lives of patients living with cancer.
At Levena BioPharma, we interface complex synthetic chemistry with antibody research providing our clients with the latest technologies and comprehensive services to advance ADC projects from discovery to IND. Our ADC platform encompasses: ADC screening tools; bioactive molecules (toxins) for research and in cGMP grade; optimized linker-toxins; conjugation services; ADC toxicity screening; and ADC optimization & processing.
MabPlex International provides one-stop, high-quality CRO/CMO solutions for biologics (mAb and ADCs) to our global clients. We are dedicated to help our clients accelerate development process and reduce manufacture costs. MabPlex has extensive experiences in manufacturing for therapeutic antibodies and antibody-drug conjugates (ADCs). Our manufacturing facilities with large-scale disposable lines and world-class instruments are operated by well-trained professionals in full compliance with U.S, European, and Chinese GMP regulations.
MilliporeSigma is the leading Life Science company, providing solutions as a strategic partner to help advance the promise of life saving therapies. We have the largest offering of products for formulations, actives and biotechnology processes. Our joint ADC offering includes a full range of integrated contract manufacturing services for drug development and manufacturing that spans conjugation, mAbs, linkers and payloads. To fit your ADC manufacturing needs, we offer a comprehensive processing portfolio from cell culture media to buffers, salts and stabilizers and from chromatography to TFF equipment, including single-use templates.
NOF CORPORATION is the leading commercial supplier of drug delivery products such as activated PEGs, lipids and ultrapure Polysorbates 20 and 80. Our cutting edge products include single molecule PEG linkers for ADCs “PIREBRIGHT Series” and SS-lipids for nucleic acid and gene delivery “COATSOME SS Series”.
SafeBridge Consultants, Inc. is the premier resource for high-level safety, health and environmental support to the pharmaceutical and biotechnology industry. Comprised of industry leaders in toxicology, analytical chemistry and industrial hygiene. SafeBridge has developed the “brand name” in the pharmaceutical industry as a leader in the field of advanced worker protection programs for potent drug handling and risk assessment for product protection. SafeBridge has locations in Mountain View, California, New York City and London, England.
Cfm Oskar Troptizsch
Minakem is a technology driven outsourcing partner dedicated to developing and manufacturing fine chemicals, advanced intermediates, APIs and HPAPIs including ADC toxins. A dedicated site having more than 40 years’ experience in high potent compounds, with state-of-the-art containment systems and capability to handle broad range of chemistry from grams to kilos scale, including preparative-HPLC, makes Minakem a partner of choice in HPAPI and ADC toxins development and supply across the full product life cycle.
Pirimal Pharmaa Solutions is a contract development and manufacturing organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our clients through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including Drug Discovery Solutions, Process & Pharmaceutical Development services, Cliinical Trial Supplies, Commercial supply of APIs and Finished dosage forms. We also offer specialized services like development and manufacture of Highly Potent APIs and Antibody Drug Conjugation. Our capibilityas an integrated service provider & experience with various technologies enables us to serve Innovator and Generic companies worldwide.
ReachBio provides primary cell biology contract research services to the drug development and life science research community. With a special focus on hematopoietic (blood and bone marrow) primary cell systems, our platform is broad and includes predictive and investigative toxicology, immunology, efficacy testing, cell bank development, biomarker selection, flow cytometry/cell sorting, and assay development and. ReachBio has developed two distinct assay platforms to assess cytotoxicity caused by ADCs.